Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTABEM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 02	STN pricing information for 2008 now available
NEWS 3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5	JAN 28	MARPAT searching enhanced
NEWS 6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9	FEB 08	STN Express, Version 8.3, now available
NEWS 10	FEB 20	PCI now available as a replacement to DPCI
NEWS 11	FEB 25	IFIREF reloaded with enhancements
NEWS 12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS 18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 29	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

```
 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:44:37 ON 26 JUN 2008

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                      0.21       0.21

FILE 'REGISTRY' ENTERED AT 18:44:44 ON 26 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   25 JUN 2008  HIGHEST RN 1030702-50-1
DICTIONARY FILE UPDATES:  25 JUN 2008  HIGHEST RN 1030702-50-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Documents and Settings\bmcdowell\My Documents\misc\10595891last.str
```





```
chain nodes :
11  20
ring nodes :
1  2  3  4  5  6  7  8  9  10  14  15  16  17  18  19
chain bonds :
9-11  18-20
ring bonds :
1-6  1-2  2-3  3-4  4-5  4-7  5-6  5-10  7-8  8-9  9-10  14-15  14-19  15-16  16-17
 17-18  18-19
exact/norm bonds :
4-7  5-10  7-8  8-9  9-10  9-11  18-20
normalized bonds :
1-6  1-2  2-3  3-4  4-5  5-6  14-15  14-19  15-16  16-17  17-18  18-19
isolated ring systems :
containing 1 :


G1:N,CH

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:CLASS  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom  20:CLASS  21:Atom



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```



G1 N,CH

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss sam
SAMPLE SEARCH INITIATED 18:45:20 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    33549 TO ITERATE

  6.0% PROCESSED     2000 ITERATIONS                                  2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:       660029 TO   681931
PROJECTED ANSWERS:             323 TO     1017

L2            2 SEA SSS SAM L1

=> d scan

L2   2 ANSWERS   REGISTRY  COPYRIGHT 2008 ACS on STN
IN   2,3-Quinoxalinedione, 6-[amino(2-iodophenyl)methyl]-1,4-dihydro-
MF   C15 H12 I N3 O2
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2   2 ANSWERS   REGISTRY  COPYRIGHT 2008 ACS on STN
IN   2(1H)-Quinolinone, 6-[(3,4-dichlorophenyl)[4-[(2-methoxyethyl)amino]-1-
     piperidinyl]methyl]-3-ethyl-
MF   C26 H31 C12 N3 O2
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 sss full
FULL SEARCH INITIATED 18:45:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 678156 TO ITERATE

100.0% PROCESSED 678156 ITERATIONS 390 ANSWERS
SEARCH TIME: 00.00.06

L3 390 SEA SSS FUL L1

=> d scan

L3 390 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Quinoxalinecarboxylic acid, 7-benzoyl-3,4-dihydro-3-oxo-, ethyl ester
MF C18 H14 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 390 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2(1H)-Quinolinone, 6-(isocyanatophenylmethyl)-3-methyl-
MF C18 H14 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 390 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzoic acid, 4-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)hydroxymethyl]-, ethyl ester
MF C20 H19 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 390 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2(1H)-Quinolinone, 6-[(2,4-difluorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl-
MF C26 H31 F2 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 390 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2(1H)-Quinolinone, 3-ethyl-6-[[4-[(2-methoxyethyl)amino]-1-piperidinyl][3-(trifluoromethoxy)phenyl]methyl]-
MF C27 H32 F3 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 390 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2(1H)-Quinoxalinone, 7-[2-(4-chlorophenyl)-2-(1H-imidazol-1-yl)ethyl]-3-ethyl-
MF C21 H19 Cl N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 390 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2(1H)-Quinolinone, 6-[(R)-1H-1,2,4-triazol-1-yl[4-(trifluoromethyl)phenyl]methyl]-, hydrobromide (1:1)
MF C19 H13 F3 N4 O . Br H

Absolute stereochemistry.



● HBr

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 390 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2(1H)-Quinolinone, 6-[1H-1,2,4-triazol-1-yl[3-
    (trifluoromethyl)phenyl]methyl]-, (S)- (9CI)
MF C19 H13 F3 N4 O

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 390 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2(1H)-Quinoxalinone, 1-amino-6-(1H-imidazol-1-ylphenylmethyl)-3-methyl-
MF C19 H17 N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 390 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2,3-Quinoxalinedione, 6-[amino(4-methylphenyl)methyl]-1,4-dihydro-
MF C16 H15 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 390 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C21 H15 N3 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 390 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinylidene]methyl]-3-ethyl-
MF C34 H36 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 390 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2(1H)-Quinolinone, 3-methyl-6-[1-phenyl-3-(1-piperidinyl)propyl]-
MF C24 H28 N2 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 390 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[[1-(phenylmethyl)-3-piperidinyl]amino]methyl]-3-ethyl-
MF C32 H35 N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 390 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[1-[(2E)-3-phenyl-2-propen-1-yl]-4-piperidinyl]methyl]-3-ethyl-
MF C34 H36 N2 O3

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):fil cap
'FIL CAP' IS NOT VALID HERE

To display more answers, enter the number of answers you would like to see. To end the display, enter "NONE", "N", "0", or "END".
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil cap

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	179.74	179.95

FILE 'CAPLUS' ENTERED AT 18:47:06 ON 26 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 26 Jun 2008 VOL 148 ISS 26
FILE LAST UPDATED: 25 Jun 2008 (20080625/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> d his

     (FILE 'HOME' ENTERED AT 18:44:37 ON 26 JUN 2008)

     FILE 'REGISTRY' ENTERED AT 18:44:44 ON 26 JUN 2008
L1   STRUCTURE UPLOADED
L2   2 S L1 SSS SAM
L3   390 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 18:47:06 ON 26 JUN 2008

=> s l3 and (py<2005)
          37 L3
    25085366 PY<2005
L4   28 L3 AND (PY<2005)

=> d 1-28 ibib abs hitstr

L4   ANSWER 1 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:430796 CAPLUS
DOCUMENT NUMBER: 141:7139
TITLE: Preparation of indolylquinoxalinones for treating
                          hyperproliferative disorders and diseases associated
                          with angiogenesis
INVENTOR(S):   Ladouceur, Gaetan H.; Bear, Brian; Bi, Cheng;
                          Brittelli, David R.; Burke, Michael J.; Chen, Gang;
                          Cook, James; Dumas, Jacques; Sibley, Robert; Turner,
                          Michael R.
PATENT ASSIGNEE(S):   Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 217 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

     PATENT NO.   KIND   DATE   APPLICATION NO.   DATE
     ------------------ ----   --------   --------------------- --------
     WO 2004043950   A1   20040527   WO 2003-US36003   20031110 <--
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2505819	A1	20040527	CA 2003-2505819		20031110 <--
AU 2003290744	A1	20040603	AU 2003-290744		20031110 <--
EP 1565455	A1	20050824	EP 2003-783328		20031110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003016169	A	20050927	BR 2003-16169		20031110
CN 1738814	A	20060222	CN 2003-80108639		20031110
JP 2006509840	T	20060323	JP 2005-507146		20031110
MX 2005PA04779	A	20050722	MX 2005-PA4779		20050504
US 20060004011	A1	20060105	US 2005-534215		20050506
NO 2005002796	A	20050609	NO 2005-2796		20050609
PRIORITY APPLN. INFO.:			US 2002-425490P	P	20021112
			US 2003-460915P	P	20030407
			US 2003-484202P	P	20030630
			WO 2003-US36003	W	20031110

OTHER SOURCE(S): MARPAT 141:7139

GI



AB The invention relates to title compds. I [wherein Ar = 6-membered aromatic ring containing 0-2 N atoms; R1 and R2 = independently H, halo, CF3, acyl, piperidinyl, piperazinyl, morpholinyl, or (un)substituted alkyl, alkoxy, amino, pyrrolidinyl, Ph, etc.; R3 = H, alkyl, OH, NO2, NH2, alkylamino, alkoxyamino, or (un)substituted benzoylamino; R4 = H, OH, halo, CN, acyl, sulfamoyl, trialkylsiloxy, tetrazolyl, thienyl, pyrrolyl, pyrimidinyl, oxazolyl, furanyl, or (un)substituted alkyl, alkenyl, alkynyl, alkoxy, amino, oxadiazolyl, Ph, pyridyl(oxy), carbamoyl; R11 and R12 = independently H, F, or Cl with the proviso that when one of R11 and R12 = F or Cl, the other must be H; and pharmaceutically acceptable salts and esters thereof]. The invention also relates to the use of I and their pharmaceutical compns. for treating hyperproliferative disorders and diseases associated with angiogenesis (no data). Examples include representative syntheses for compds. of the invention, pharmaceutical compns. comprising them, and tumor model assays (no specific data given). For instance, N-Boc-indole was coupled with di-Me oxalate using t-BuLi to give tert-Bu 2-[methoxy(oxo)acetyl]-1H-indole-1-carboxylate (72%). Cyclization of the dione with 1,2-phenylenediamine in AcOH afforded the quinoxalinone II (77%).

IT 694531-84-5P 694531-85-6P 694531-86-7P

694531-90-3P 694531-93-6P 694531-94-7P
694532-04-2P 694532-29-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiproliferative and angiogenesis inhibitor; preparation of indolylquinoxalinones for treating hyperproliferative disorders and diseases associated with angiogenesis)

RN 694531-84-5 CAPLUS
CN 2(1H)-Quinoxalinone, 3-[3-amino-5-[[(3S)-3-(dimethylamino)-1-pyrrolidinyl]carbonyl]-1H-indol-2-yl]-6-benzoyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 694531-85-6 CAPLUS
CN 2(1H)-Quinoxalinone, 3-[3-amino-5-[[4-(2-methoxyethyl)-1-piperazinyl]carbonyl]-1H-indol-2-yl]-6-benzoyl- (CA INDEX NAME)



RN 694531-86-7 CAPLUS
CN 2(1H)-Quinoxalinone, 3-[3-amino-5-(1-piperidinylcarbonyl)-1H-indol-2-yl]-6-benzoyl- (CA INDEX NAME)



RN 694531-90-3 CAPLUS
CN 1H-Indole-5-carboxamide, 3-amino-2-(6-benzoyl-3,4-dihydro-3-oxo-2-quinoxalinyl)-N-(2-methoxyethyl)-N-methyl- (CA INDEX NAME)



RN 694531-93-6 CAPLUS
CN 2(1H)-Quinoxalinone, 3-[3-amino-5-(1-pyrrolidinylcarbonyl)-1H-indol-2-yl]-6-benzoyl- (CA INDEX NAME)



RN 694531-94-7 CAPLUS
CN 2(1H)-Quinoxalinone, 3-[3-amino-5-(1-pyrrolidinylcarbonyl)-1H-indol-2-yl]-7-benzoyl- (CA INDEX NAME)



RN 694532-04-2 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-amino-2-(7-benzoyl-3,4-dihydro-3-oxo-2-quinoxalinyl)- (CA INDEX NAME)



RN 694532-29-1 CAPLUS
CN 2(1H)-Quinoxalinone, 3-[3-amino-5-[[(3S)-3-(dimethylamino)-1-pyrrolidinyl]carbonyl]-1H-indol-2-yl]-7-benzoyl- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:796538 CAPLUS
DOCUMENT NUMBER: 139:323440
TITLE: Preparation of radiolabeled quinolines and quinolinones as metabotropic glutamate receptor mGluR1 antagonists for use in positron emission tomography.
INVENTOR(S): Lesage, Anne Simone Josephine; Bischoff, Francois Paul; Janssen, Cornelus Gerardus Maria; Lavreysen, Hilde
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082350	A2	20031009	WO 2003-EP3240	20030326 <--
WO 2003082350	A3	20040304		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2479109	A1	20031009	CA 2003-2479109	20030326 <--
AU 2003226737	A1	20031013	AU 2003-226737	20030326 <--
BR 2003008945	A	20050104	BR 2003-8945	20030326
EP 1492571	A2	20050105	EP 2003-745282	20030326
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1642580	A	20050720	CN 2003-807387	20030326
JP 2005524679	T	20050818	JP 2003-579882	20030326
NZ 535438	A	20060831	NZ 2003-535438	20030326
IN 2004DN02631	A	20050401	IN 2004-DN2631	20040908
US 20060083676	A1	20060420	US 2004-509069	20040924
MX 2004PA09435	A	20050125	MX 2004-PA9435	20040928
ZA 2004007820	A	20051011	ZA 2004-7820	20040928

NO 2004004635 A 20041027 NO 2004-4635 20041027 <--
PRIORITY APPLN. INFO.: EP 2002-76254 A 20020329
WO 2003-EP3240 W 20030326

OTHER SOURCE(S): MARPAT 139:323440

GI


I


II


III

AB Radiolabeled title compds. [I, II; X = O, S, C(R6)2, NR7; Y = O, S; R1 = (substituted) alkyl, cycloalkyl, cycloalkylalkyl, thienyl, quinolinyl, etc.; R2 = H, halo, cyano, alkyl, amino, heterocyclyl, etc.; R3, R4 = H, halo, OH, cyano, alkyl, alkoxy, etc.; R2R3 = (CH2)3-6, Z4CH2CH2CH2, Z4CH2CH2, etc.; Z4 = O, S, SO2, NR11; R11 = H, alkyl, PhCH2, alkoxycarbonyl; R3R4 = (CH2)4, CH:CHCH:CH; R5 = H, cycloalkyl, piperidinyl, oxothienyl, tetrahydrothienyl, aralkyl, alkoxyalkyl, etc.; R6 = H, aryl, alkyl, aminoalkyl; R7 = amino, OH], were prepared Most preferred are radiolabeled compds. in which the radioactive isotope is selected from 3H, 11C and 18F. The invention also relates to their use in a diagnostic method, in particular for marking and identifying a mGluR1 receptor in biol. material, as well as to their use for imaging an organ, in particular using positron emission tomog. (PET). Thus, title compound (III) was prepared by tritiation of the corresponding bromide in THF using tritium gas and Pd/C catalyst. The purified product showed specific activity of 25 Ci/mmol.

IT 409344-47-4P 409344-48-5P 409344-56-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of radiolabeled quinolines and quinolinones as metabotropic glutamate receptor mGluR1 antagonists for use in positron emission tomog.)

RN 409344-47-4 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-(2-phenylacetyl)- (CA INDEX NAME)



RN 409344-48-5 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[2-(2-methoxyphenyl)acetyl]- (CA INDEX NAME)



RN 409344-56-5 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-(1-oxo-3-phenylpropyl)- (CA INDEX NAME)



L4 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:235032 CAPLUS
DOCUMENT NUMBER: 139:143344
TITLE: Synthesis and SAR of novel di- and trisubstituted 1,4-dihydroquinoxaline-2,3-diones related to licostinel (Acea 1021) as NMDA/glycine site antagonists
AUTHOR(S): Zhou, Zhang-Lin; Kher, Sunil M.; Cai, Sui Xiong; Whittemore, Edward R.; Espitia, Stephen A.; Hawkinson, Jon E.; Tran, Minhtam; Woodward, Richard M.; Weber, Eckard; Keana, John F. W.
CORPORATE SOURCE: Department of Chemistry, University of Oregon, Eugene, OR, 97403, USA
SOURCE: Bioorganic & Medicinal Chemistry (2003), 11(8), 1769-1780
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:143344

AB A series of novel di- and trisubstituted 1,4-dihydroquinoxaline-2,3-diones (QXs) related to licostinel (Acea 1021) was synthesized and evaluated as antagonists for the glycine site of the N-methyl-d-aspartate (NMDA) receptor. The in vitro potency of these antagonists was determined by displacement of the glycine site radioligand [3H]-5,7-dichlorokynurenic acid ([3H]DCKA) in rat brain cortical membranes. Structure-activity relationship studies indicate that a cyano group is a good replacement for the nitro group in the 5-position of licostinel while 5-carboxy, 5-ester, 5-ketone and 5-amide derivs. showed reduced potency. 5,6-Cyclized analogs of licostinel also showed significantly reduced potency. Among the trisubstituted QXs investigated, 5-cyano-6,7-dichloro QX and 5-cyano-7-chloro-6-Me QX are the most potent with IC50 values of 32 nM and 26 nM, resp.

IT 573692-50-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and structure-activity relationship of novel di- and trisubstituted 1,4-dihydroquinoxaline-2,3-diones related to licostinel

(Acea 1021) as NMDA/glycine site antagonists)
RN 573692-50-9 CAPLUS
CN 2,3-Quinoxalinedione, 5-benzoyl-7-chloro-1,4-dihydro- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:574925 CAPLUS
DOCUMENT NUMBER: 137:140442
TITLE: Preparation of 1,5-diaryl-7-heterocyclyl(alkyl)-2-quinolinones as p38 protein kinase inhibitors
INVENTOR(S): Doherty, James B.; Stelmach, John E.; Chen, Meng-Hsin; Liu, Luping; Hunt, Julianne A.; Ruzek, Rowena D.; Goulet, Joung L.; Wisnoski, David D.; Natarajan, Swaminathan Ravi; Rupprecht, Kathleen M.; Bao, Jianming; Miao, Shouwu; Hong, Xingfang
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 440 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002058695	A1	20020801	WO 2001-US48676	20011214 <--
WO 2002058695	A9	20030912		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2431904	A1	20020801	CA 2001-2431904	20011214 <--
AU 2002246677	A1	20020806	AU 2002-246677	20011214 <--
AU 2002246677	B2	20061116		
EP 1345603	A1	20030924	EP 2001-994260	20011214 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004521892	T	20040722	JP 2002-559029	20011214 <--
US 20030092712	A1	20030515	US 2001-23231	20011217 <--
US 6809199	B2	20041026		

PRIORITY APPLN. INFO.:		
US 2000-256822P	P	20001220
WO 2001-US48676	W	20011214

OTHER SOURCE(S): MARPAT 137:140442
GI



I

AB Title compds. were prepared Thus, 2,6-dibromo-4-methoxytoluene was converted in 5 steps to arylquinolinone I (R1 = Br, R2 = OMe) which was condensed with 2,4-F2C6H3B(OH)2 and the O-demethylated product converted in 4 steps to I (R1 = C6H3F2-2,4, R2 = 4-piperidinyl). Data for biol. activity of title compds. were given.

IT 444664-57-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1,5-diaryl-7-heterocyclyl(alkyl)-2-quinolinones as p38 protein kinase inhibitors)

RN 444664-57-7 CAPLUS

CN 2(1H)-Quinolinone, 5-(2-chloro-4-fluorophenyl)-1-(2,6-difluorophenyl)-7-(triphenylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:275968 CAPLUS
DOCUMENT NUMBER: 136:309857
TITLE: Preparation of quinolines and quinolinones as metabotropic glutamate receptor antagonists
INVENTOR(S): Mabire, Dominique Jean-Pierre; Venet, Marc Gaston; Coupa, Sophie; Poncelet, Alain Philippe; Lesage, Anne

Simone Josephine
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2002028837	A1	20020411	WO 2001-EP11135	20010925	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2421782	A1	20020411	CA 2001-2421782	20010925	<--
AU 2001093847	A	20020415	AU 2001-93847	20010925	<--
BR 2001014253	A	20030701	BR 2001-14253	20010925	<--
EP 1332133	A1	20030806	EP 2001-974298	20010925	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
HU 2003002167	A2	20031028	HU 2003-2167	20010925	<--
JP 2004510764	T	20040408	JP 2002-532423	20010925	<--
NZ 524945	A	20050128	NZ 2001-524945	20010925	
EE 200300126	A	20050415	EE 2003-126	20010925	
CN 1703403	A	20051130	CN 2001-816717	20010925	
AU 2001293847	B2	20070524	AU 2001-293847	20010925	
KR 818965	B1	20080404	KR 2003-702014	20030211	
HR 2003000229	A1	20030630	HR 2003-229	20030324	<--
IN 2003MN00328	A	20050211	IN 2003-MN328	20030324	
BG 107672	A	20040130	BG 2003-107672	20030326	<--
ZA 2003002515	A	20040630	ZA 2003-2515	20030331	<--
NO 2003001474	A	20030505	NO 2003-1474	20030401	<--
NO 325079	B1	20080128			
MX 2003PA02907	A	20030624	MX 2003-PA2907	20030401	<--
US 20040082592	A1	20040429	US 2003-381987	20030814	<--
US 7115630	B2	20061003			
US 20050209273	A1	20050922	US 2005-133678	20050520	

PRIORITY APPLN. INFO.:			
EP 2000-203419	A	20001002	
WO 2001-EP11135	W	20010925	
US 2003-381987	A3	20030814	

OTHER SOURCE(S): MARPAT 136:309857
GI



I



II



III

AB The title compds. [I or II; X = O, C(R6)2; (wherein R6 = H, aryl, alkyl, etc.); R1 = alkyl, aryl, thienyl, etc.; R2 = H, halo, CN, etc.; R3, R4 = H, alkyl; or R2 and R3 may be taken together to form (CH2)3, (CH2)4, CH:CHCH:CH, etc.; or R3 and R4 may be taken together to form CH:CHCH:CH, (CH2)4; R5 = H, cycloalkyl, piperidinyl, etc.; Y = O, S; or Y and R5 may be taken together to form CH:NN, N:NN, NCH:CH], useful for treating or preventing glutamate-induced diseases of the central nervous system, were prepared Thus, reacting cis-III [R = Cl] with SnMe4 in the presence of Pg(PPh3)4 in PhMe afforded 17% cis-III [R = Me] which showed antagonism at a dose of 2.5 mg/kg bodyweight in cold allodynia test in rats with a Bennett ligation.

IT 409344-47-4P 409344-48-5P 409344-56-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinolines and quinolinones as metabotropic glutamate receptor antagonists)

RN 409344-47-4 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-(2-phenylacetyl)- (CA INDEX NAME)



RN 409344-48-5 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[2-(2-methoxyphenyl)acetyl]- (CA INDEX NAME)



RN 409344-56-5 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-(1-oxo-3-phenylpropyl)- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:222670 CAPLUS
DOCUMENT NUMBER: 137:241668
TITLE: Phosphonate quinoxalinedione AMPA antagonists for therapy of stroke and trauma
AUTHOR(S): Ottow, Eckhard; Huth, Andreas; Kruger, Martin; Schneider, Herbert H.; Neuhaus, Roland; McDonald, Fiona; Lofberg, Boel; Turski, Lechoslaw
CORPORATE SOURCE: Research Laboratories of Schering AG, Berlin, D-13342, Germany
SOURCE: Biomedical and Health Research (2001), 45(Excitatory Amino Acids: Ten Years Later), 329-344
CODEN: BIHREN; ISSN: 0929-6743
PUBLISHER: IOS Press
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:241668

AB Glutamate antagonists derived from the quinoxalinedione scaffold are drug candidates for neuroprotection in stroke and trauma. Quinoxalinedione derivs. such as 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline and 6-(1H-imidazol-1-yl)-7-nitro-2,3-(1H,4H)-quinoxalinedione failed clin. trials because of insoly. and resulting nephrotoxicity. Introduction of phosphonate group into the quinoxalinedione skeleton improves solubility and leaves potency for the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor unchanged. Phosphonate quinoxalinedione derivs. ZK200775 and ZK202000 protect rodent brain against ischemic and traumatic brain injury. No major deleterious effects on motor coordination, cardiovascular, or respiratory systems are detected in doses required for neuroprotection. No psychotomimetic and no neurotoxic side effects in the brain are observed after treatment with phosphonate quinoxalinediones.

IT 191740-32-6P, ZK202000
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phosphonate quinoxalinedione AMPA antagonists for therapy of stroke and trauma)

RN 191740-32-6 CAPLUS
CN Phosphonic acid, [[3,4-dihydro-2,3-dioxo-7-(2-phenylethyl)-6-(trifluoromethyl)-1(2H)-quinoxalinyl]methyl]- (9CI) (CA INDEX NAME)



IT 191740-18-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(phosphonate quinoxalinedione AMPA antagonists for therapy of stroke and trauma)
RN 191740-18-8 CAPLUS
CN Phosphonic acid, [[3,4-dihydro-2,3-dioxo-7-(2-phenylethyl)-6-(trifluoromethyl)-1(2H)-quinoxalinyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:482884 CAPLUS
DOCUMENT NUMBER: 135:239238
TITLE: A novel quinoline alkaloid possessing a 7-benzyl group from the centipede, Scolopendra subspinipes
AUTHOR(S): Noda, Naoki; Yashiki, Yuji; Nakatani, Takafumi; Miyahara, Kazumoto; Du, Xiao-Ming
CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, 573-0101, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (2001), 49(7), 930-931
CODEN: CPBTAL; ISSN: 0009-2363
PUBLISHER: Pharmaceutical Society of Japan
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The novel quinoline alkaloid scolopendrine was isolated from the centipede, Scolopendra subspinipes mutilans L. Koch. The structure was determined to be 2-hydroxy-7-[(4-hydroxy-3-methoxyphenyl)methyl]-3-methoxy-8-quinolyl sulfate on the basis of high-resolution electron-spray ionization mass spectroscopy and two-dimensional NMR spectral data. Unlike quinoline alkaloids so far reported, scolopendrine is unique in having a 7-benzyl moiety in the quinoline ring.
IT 360550-09-0, Scolopendrine
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); RCT (Reactant); BIOL (Biological study); OCCU (Occurrence); RACT (Reactant or reagent)
(quinoline alkaloid from Scolopendra subspinipes)
RN 360550-09-0 CAPLUS

CN 2(1H)-Quinolinone, 7-[(4-hydroxy-3-methoxyphenyl)methyl]-3-methoxy-8-(sulfooxy)- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:476381 CAPLUS
DOCUMENT NUMBER: 135:100164
TITLE: (R)-1-{(2-Oxo-1,2-dihydroquinolin-6-yl)[3-(trifluoromethyl)phenyl]methyl}-1H-1,2,4-triazol-4-ium bromide
AUTHOR(S): Peeters, Oswald M.; Blaton, Norbert M.; De Ranter, Camiel J.
CORPORATE SOURCE: Faculteit Farmaceutische Wetenschappen, Laboratorium voor Analytische Chemie en Medicinale Fysicochemie, Katholieke Universiteit Leuven, Louvain, B-3000, Belg.
SOURCE: Acta Crystallographica, Section E: Structure Reports Online (2001), E57(7), o655-o656
CODEN: ACSEBH; ISSN: 1600-5368
URL: http://journals.iucr.org/e/issues/2001/07/00/ya6033/ya6033.pdf
PUBLISHER: International Union of Crystallography
DOCUMENT TYPE: Journal; (online computer file)
LANGUAGE: English

AB The metabolism of all-trans-retinoic acid is mediated by a cytochrome dependent P 450 system. The title compound, C19H14F3N4O+·Br- (R111214), is an inhibitor of P 450. The three planar ring systems, viz. the triazolyl, Ph and quinolinone groups, are arranged in a propeller-like fashion around the central CH group. The dihedral angles formed by the triazolyl/phenyl, triazolyl/quinolinone and phenyl/quinolinone planes are 55.8(1), 79.85(9) and 78.49(9)°, resp. The N-H...O H bonds, involving the triazolium N-H group and the quinolinone O atom, link the cations into infinite chains stretching along the c axis of the crystal. Crystallog. data are given.

IT 349553-99-7
RL: PRP (Properties)
(crystal structure of)
RN 349553-99-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[(R)-1H-1,2,4-triazol-1-yl[4-(trifluoromethyl)phenyl]methyl]-, hydrobromide (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HBr

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:223060 CAPLUS
DOCUMENT NUMBER: 135:5590
TITLE: Some nucleophilic reactions with 6-benzoyl-2,3-dichloroquinoxaline: synthesis of tetrazolo[1,5-a]quinoxline, 2-methylidene-1,3-dithiolo[4,5-b]quinoxalines, quinoxalino[2,3-b]quinoxalines and pyrazolo[1',5':1,2]imidazolo[4,5-b]-quinoxalines
AUTHOR(S): El-Gaby, M. S. A.; El-Sharief, A. M. Sh; Ammar, Y. A.; Mohamed, Y. A.; El-Salam, A. A. Abd
CORPORATE SOURCE: Department of Chemistry, Faculty of Science, Al-Azhar University at Assiut, Assiut, 71524, Egypt
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (2001), 40B(3), 195-200
CODEN: IJSBDB; ISSN: 0376-4699
PUBLISHER: National Institute of Science Communication, CSIR
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:5590
AB The starting material 6-benzoyl-2,3-dichloroquinoxaline is subjected to some nucleophilic reagents to study the effect of the benzoyl group on the reactivity of the two chlorine atoms.
IT 143702-68-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactions of 6-benzoyl-2,3-dichloroquinoxaline with nucleophiles)
RN 143702-68-5 CAPLUS
CN 2,3-Quinoxalinedione, 6-benzoyl-1,4-dihydro- (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:868071 CAPLUS
DOCUMENT NUMBER: 135:55887
TITLE: Phosphonate quinoxalinedione AMPA antagonists
AUTHOR(S): Turski, Lechoslaw; Schneider, Herbert H.; Neuhaus, Roland; McDonald, Fiona; Jones, Graham H.; Lofberg, Boel; Schweinfurth, Hermann; Huth, Andreas; Kruger, Martin; Ottow, Eckhard
CORPORATE SOURCE: Research Laboratories of Schering AG, Berlin, D-13342, Germany
SOURCE: Restorative Neurology and Neuroscience (2000), 17(1), 45-59
CODEN: RNNEEL; ISSN: 0922-6028
PUBLISHER: IOS Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In the Western world, over 350,000 deaths and $30 billion in medical costs are attributed annually to stroke. Head and spinal cord trauma cause an estimated 250,000 deaths annually and result in medical costs of $15 billion. Although stroke and head/spinal cord trauma are leading causes of disability and death in humans, no adequate neuroprotective treatment is available. Glutamate antagonists derived from the quinoxalinedione scaffold are as drug candidates for neuroprotection in stroke and trauma. Quinoxalinedione derivs. such as 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline and 6-(1H-imidazol-1-yl)-7-nitro-2,3-(1H,4H)-quinoxalinedione failed clin. trials because of insoly. and resulting nephrotoxicity. Introduction of a phosphonate group into the quinoxalinedione skeleton improves solubility and leaves potency for the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor unchanged. Phosphonate quinoxalinedione derivs. ZK202000 and ZK200775 protected rodent brain against sequelae of permanent occlusion of the middle cerebral artery and head trauma. No major deleterious effects on motor coordination, cardiovascular, or respiratory systems were detected in doses required for neuroprotection. No psychotomimetic and no neurotoxic side effects, typical for N-methyl-D-aspartate antagonists, were observed following treatment with phosphonate quinoxalinediones.

IT 191740-32-6P, ZK 202000
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(phosphonate quinoxalinedione AMPA antagonists as neuroprotectants in stroke and trauma)

RN 191740-32-6 CAPLUS
CN Phosphonic acid, [[3,4-dihydro-2,3-dioxo-7-(2-phenylethyl)-6-(trifluoromethyl)-1(2H)-quinoxalinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:527827 CAPLUS
DOCUMENT NUMBER: 134:162992
TITLE: Synthesis and antimicrobial activities of some novel quinoxalinone derivatives
AUTHOR(S): Ali, M. M.; Ismail, M. M. F.; El-Gaby, M. S. A.; Zahran, M. A.; Ammar, Y. A.
CORPORATE SOURCE: Dep. of Chemistry, Faculty of Science, Al-Azhar Univ., Cairo, 11884, Egypt
SOURCE: Molecules [online computer file] (2000), 5(6), 864-873
CODEN: MOLEFW; ISSN: 1420-3049
URL: http://www.mdpi.org/molecules/papers/50600864.pdf
PUBLISHER: Molecular Diversity Preservation International
DOCUMENT TYPE: Journal; (online computer file)
LANGUAGE: English
OTHER SOURCE(S): CASREACT 134:162992
GI



AB Condensation of 4-benzoyl-1,2-phenylenediamine with sodium pyruvate in acetic acid furnished two products, which were identified as 6-benzoyl-(I) and 7-benzoyl-3-methyl-2(1H)-quinoxalinone (II). Fusion of I with aromatic aldehydes furnished the styryl derivs. Alkylation of I and II with di-Me sulfate or Et chloroacetate produced the N-alkyl derivs. Hydrazinolysis of one ester derivative with hydrazine hydrate afforded the hydrazide derivative, which underwent condensation with aldehydes to give the corresponding hydrazone derivs. In addition, chlorination of I with thionyl chloride afforded the 2-chloro derivative, which was subjected to reaction with sodium azide and n-butylamine to yield the corresponding tetrazolo (III) and n-butylamino (IV) derivs., resp. The structures of the compds. prepared were confirmed by anal. and spectral data. Also, some of the synthesized compds. were screened for antimicrobial activity.
IT 325469-51-0P 325469-52-1P 325469-58-7P
325469-60-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation and antimicrobial activities of quinoxalinone derivs.)
RN 325469-51-0 CAPLUS
CN 2(1H)-Quinoxalinone, 6-benzoyl-3-methyl- (CA INDEX NAME)



RN 325469-52-1 CAPLUS
CN 2(1H)-Quinoxalinone, 7-benzoyl-3-methyl- (CA INDEX NAME)



RN 325469-58-7 CAPLUS
CN 1(2H)-Quinoxalineacetic acid, 6-benzoyl-3-methyl-2-oxo-, ethyl ester (CA INDEX NAME)



RN 325469-60-1 CAPLUS
CN 1(2H)-Quinoxalineacetic acid, 6-benzoyl-3-methyl-2-oxo-, hydrazide (CA INDEX NAME)



IT 325469-54-3P 325469-59-8P 325469-62-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antimicrobial activities of quinoxalinone derivs.)

RN 325469-54-3 CAPLUS
CN 2(1H)-Quinoxalinone, 6-benzoyl-3-[(1E)-2-(4-methoxyphenyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 325469-59-8 CAPLUS
CN 1(2H)-Quinoxalineacetic acid, 7-benzoyl-3-methyl-2-oxo-, ethyl ester (CA INDEX NAME)



RN 325469-62-3 CAPLUS
CN 1(2H)-Quinoxalineacetic acid, 6-benzoyl-3-methyl-2-oxo-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

IT 325469-53-2P 325469-55-4P 325469-56-5P
325469-57-6P 325469-61-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antimicrobial activities of quinoxalinone derivs.)
RN 325469-53-2 CAPLUS
CN 2(1H)-Quinoxalinone, 6-benzoyl-3-[(1E)-2-(4-chlorophenyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 325469-55-4 CAPLUS
CN 2(1H)-Quinoxalinone, 6-benzoyl-3-[(1E)-2-(3,4,5-trimethoxyphenyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 325469-56-5 CAPLUS
CN 2(1H)-Quinoxalinone, 6-benzoyl-1,3-dimethyl- (CA INDEX NAME)



RN 325469-57-6 CAPLUS
CN 2(1H)-Quinoxalinone, 7-benzoyl-1,3-dimethyl- (CA INDEX NAME)



RN 325469-61-2 CAPLUS
CN 1(2H)-Quinoxalineacetic acid, 6-benzoyl-3-methyl-2-oxo-,
2-(phenylmethylene)hydrazide (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:672545 CAPLUS

DOCUMENT NUMBER: 129:275932
ORIGINAL REFERENCE NO.: 129:56265a,56268a
TITLE: Preparation of 3-oxadiazolylquinoxaline derivatives having affinity to benzodiazepine receptor
INVENTOR(S): Ohno, Kazunori; Odai, Osamu; Furukawa, Kiyoshi; Oka, Makoto
PATENT ASSIGNEE(S): Dainippon Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9842701	A1	19981001	WO 1998-JP827	19980227 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
JP 2002241379	A	20020828	JP 1997-87646	19970321 <--
AU 9861179	A	19981020	AU 1998-61179	19980227 <--

PRIORITY APPLN. INFO.: JP 1997-87646 A 19970321
WO 1998-JP827 W 19980227

OTHER SOURCE(S): MARPAT 129:275932
GI



AB Novel 3-oxadiazolylquinoxaline derivs. represented by general formula (I; wherein Het is oxadiazolyl; R1 is hydrogen, lower alkyl, trifluoromethyl, lower cycloalkyl, lower alkenyl, lower alkynyl, optionally substituted aryl, optionally substituted heteroaryl, or lower alkoxy; R2 is hydrogen, lower alkyl, trifluoromethyl, lower cycloalkyl, halogeno, hydroxy, lower alkoxy, cyano, nitro, acyl, optionally substituted benzoyl, amino, lower mono- or dialkylamino, lower alkoxycarbonylmethyloxy, lower mono- or dialkylaminocarbonylmethyloxy, or optionally substituted benzyloxy; and R3 is hydrogen, lower alkyl, lower cycloalkyl, halogeno, or lower alkoxy), which are useful as a medicine, in particular, which have a selective affinity for benzodiazepine receptors and are useful as a brain activator and a remedy for senile dementia and Alzheimer's disease. Thus, a solution of 1,2-dihydro-2-oxo-3-quinoxalinecarboxylic acid and N,N'-carbonyl diimidazole in DMF was heated with stirring for 3 h at 60°, followed by adding acetamidoxime, and the stirring was continued for another 1.5 h to give 52.6% the title compound (II; R1 = Me; R2 = H). The latter compound and I (R1 = Et, R2 = OMe) inhibited the binding of [3H]diazepam to synaptosome membrane fraction prepared from rat brain with IC50 of 11.5 and 1.41 nM, resp.

IT 213743-73-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxadiazolylquinoxaline derivs. having affinity to benzodiazepine receptor as brain activators and remedies for senile dementia and Alzheimer's disease)
RN 213743-73-8 CAPLUS
CN 2(1H)-Quinoxalinone, 6-benzoyl-3-(3-ethyl-1,2,4-oxadiazol-5-yl)- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:210752 CAPLUS
DOCUMENT NUMBER: 128:257445
ORIGINAL REFERENCE NO.: 128:50967a,50970a
TITLE: Preparation of indolylbenzoquinoxalinones and related compounds as protein kinase C inhibitors.
INVENTOR(S): Bergstrand, Hakan; Karabelas, Kostas; Sjo, Peter
PATENT ASSIGNEE(S): Astra Aktiebolag (Publ), Swed.
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9813368	A1	19980402	WO 1997-SE1582	19970919 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
IN 1997DE02638	A	20050311	IN 1997-DE2638	19970916
TW 472045	B	20020111	TW 1997-86113549	19970918 <--
ZA 9708469	A	19980325	ZA 1997-8469	19970919 <--
CA 2265854	A1	19980402	CA 1997-2265854	19970919 <--
AU 9744775	A	19980417	AU 1997-44775	19970919 <--
AU 716279	B2	20000224		
EP 929551	A1	19990721	EP 1997-943259	19970919 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NZ 334531	A	20000929	NZ 1997-334531	19970919 <--
US 6271231	B1	20010807	US 1997-981266	19971218 <--
US 20010025043	A1	20010927	US 2001-865231	20010525 <--

PRIORITY APPLN. INFO.:

SE 1996-3505	A	19960925
SE 1997-2747	A	19970718
WO 1997-SE1582	W	19970919
US 1997-981266	A3	19971218

OTHER SOURCE(S): MARPAT 128:257445

GI



I

AB Title compds. [I; A, X, Y, Z = C, N; ≥2 of A, X, Y, Z = C; may be substituted and/or annulated; excluding 3-(1H-indol-3-yl)-1H-quinoxalin-2-one, 3-(2-methyl-1H-indol-3-yl)-1H-quinoxalin-2-one, and 3-(1,2-diphenyl-1H-indol-3-yl)-1H-quinoxalin-2-one], were prepared as protein kinase C inhibitors (no data). Thus, 1,2-phenylenediamine was stirred overnight with [1-[3-(1,3-dioxoisoindol-2-yl)propyl]-1H-indol-3-yl]oxoacetic acid 2,5-dioxopyrrolidin-1-yl ester (preparation given) in THF to give 3-[3-(3-oxo-3,4-dihydroquinoxalin-2-yl)indol-1-yl]propylammonium acetate. The latter was stirred with MeNH2 in THF/H2O to give 3=[3-(3-oxo-3,4-dihydroquinoxalin-2-yl)indol-1-yl]propylammonium acetate.

IT 205377-65-7P 205377-77-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indolylbenzoquinoxalinones and related compds. as protein kinase C inhibitors)

RN 205377-65-7 CAPLUS

CN 2(1H)-Quinoxalinone, 3-[1-(3-aminopropyl)-1H-indol-3-yl]-1-methyl-6-(phenylmethyl)-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 205377-64-6
CMF C27 H26 N4 O



CM 2

CRN 64-19-7

CMF C2 H4 O2

RN 205377-77-1 CAPLUS
CN 2(1H)-Quinoxalinone, 3-[1-(3-aminopropyl)-1H-indol-3-yl]-6-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 205377-76-0
CMF C26 H24 N4 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:447997 CAPLUS
DOCUMENT NUMBER: 127:81611
ORIGINAL REFERENCE NO.: 127:15657a
TITLE: Preparation of novel quinoxalinedione derivatives as medicaments
INVENTOR(S): Huth, Andreas; Krueger, Martin; Ottow, Eckhard; Seidelmann, Dieter; Neuhaus, Roland; Schneider, Herbert; Turski, Lechoslaw
PATENT ASSIGNEE(S): Schering A.-G., Germany
SOURCE: Ger. Offen., 9 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

DE 19545251	A1	19970528	DE 1995-19545251	19951124 <--
CA 2238023	A1	19970529	CA 1996-2238023	19961115 <--
WO 9719066	A1	19970529	WO 1996-DE2227	19961115 <--
W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9718674	A	19970611	AU 1997-18674	19961115 <--
AU 720083	B2	20000525		
EP 876357	A1	19981111	EP 1996-946000	19961115 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1202891	A	19981223	CN 1996-198529	19961115 <--
JP 2000500471	T	20000118	JP 1997-519292	19961115 <--
HU 9902041	A2	20000428	HU 1999-2041	19961115 <--
HU 9902041	A3	20000728		
ZA 9609832	A	19970617	ZA 1996-9832	19961122 <--
NO 9802349	A	19980701	NO 1998-2349	19980522 <--

PRIORITY APPLN. INFO.: DE 1995-19545251 A 19951124
WO 1996-DE2227 W 19961115

OTHER SOURCE(S): MARPAT 127:81611

GI



I

AB The preparation of title compds. I (R1 = phosphonyl, sulfonyl, or carboxy substituted organo, cyanoorgano, tetrazolylorgano, etc.; R5 = substituted amino, thionyl, carbonyl, etc.; R6, R7 = same or different H, halo, NO2, cyano, substituted amino, carbonyl, alkoxy, hetaryl, etc.), useful as medicaments for central nerves system, is described. Thus, [(6-trifluoromethyl-7-[N-oxy-(N-isopropylformylimino)]-1,2,3,4-tetrahydroquinoxalin-2,3-dion)-1-yl]methanephosphonic acid was prepared in several steps starting from aminomethanephosphonic acid.

IT 191740-18-8P 191740-19-9P 191740-20-2P
191740-21-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of novel quinoxalinedione derivs. as medicaments)

RN 191740-18-8 CAPLUS

CN Phosphonic acid, [[3,4-dihydro-2,3-dioxo-7-(2-phenylethyl)-6-(trifluoromethyl)-1(2H)-quinoxalinyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 191740-19-9 CAPLUS
CN Phosphonic acid, [[7-[2-(4-chlorophenyl)ethyl]-3,4-dihydro-2,3-dioxo-6-(trifluoromethyl)-1(2H)-quinoxalinyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 191740-20-2 CAPLUS
CN Phosphonic acid, [[7-[2-(4-fluorophenyl)ethyl]-3,4-dihydro-2,3-dioxo-6-(trifluoromethyl)-1(2H)-quinoxalinyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 191740-21-3 CAPLUS
CN Phosphonic acid, [[3,4-dihydro-7-[2-(4-methoxyphenyl)ethyl]-2,3-dioxo-6-(trifluoromethyl)-1(2H)-quinoxalinyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



IT 191740-32-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of novel quinoxalinedione derivs. as medicaments)
RN 191740-32-6 CAPLUS
CN Phosphonic acid, [[3,4-dihydro-2,3-dioxo-7-(2-phenylethyl)-6-(trifluoromethyl)-1(2H)-quinoxalinyl]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:527663 CAPLUS
DOCUMENT NUMBER: 125:167994
ORIGINAL REFERENCE NO.: 125:31485a,31488a
TITLE: Preparation of 6-[triazolyl(3-trifluoromethylphenyl)methyl]-2-quinolin(thi)ones for treatment of keratinization disorders
INVENTOR(S): Venet, Marc Gaston; Mabire, Dominique Jean-Pierre; Sanz, Gerard Charles
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9620200	A1	19960704	WO 1995-EP5173	19951221	<--
W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN					
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
IN 1995CA01685	A	20050304	IN 1995-CA1685	19951220	
CA 2207268	A1	19960704	CA 1995-2207268	19951221	<--
AU 9644362	A	19960719	AU 1996-44362	19951221	<--
AU 698199	B2	19981029			
EP 800524	A1	19971015	EP 1995-943237	19951221	<--
EP 800524	B1	20011031			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE					
CN 1171789	A	19980128	CN 1995-197162	19951221	<--
CN 1085668	B	20020529			
JP 10511654	T	19981110	JP 1995-520222	19951221	<--
BR 9510504	A	19990601	BR 1995-10504	19951221	<--
RU 2165419	C2	20010420	RU 1997-112898	19951221	<--
AT 207924	T	20011115	AT 1995-943237	19951221	<--
PT 800524	T	20020429	PT 1995-943237	19951221	<--
ES 2166838	T3	20020501	ES 1995-943237	19951221	<--
PL 182956	B1	20020531	PL 1995-321041	19951221	<--
ZA 9510989	A	19970627	ZA 1995-10989	19951227	<--

IL 116577	A	20000229	IL 1995-116577		19951227 <--
US 5922734	A	19990713	US 1997-860239		19970616 <--
FI 9702794	A	19970627	FI 1997-2794		19970627 <--
NO 9703029	A	19970627	NO 1997-3029		19970627 <--
NO 311220	B1	20011029			
PRIORITY APPLN. INFO.:			EP 1994-203773	A	19941228
			WO 1995-EP5173	W	19951221

OTHER SOURCE(S): MARPAT 125:167994

GI



I

AB Title compds. [I; R = 3-(F3C)C6H4][II; R1 = H, NH2, alkyl; R2,R3 = H, halo, alkyl; X = O or S; 1 of Z1,Z2 = N and the other = CH] were prepared Thus, (R)-II (R1-R3 = H, X = O, Z1 = N, Z2 = CH) gave complete suppression of estradiol undecylate-induced vaginal keratinization in 50% of ovariectomized rats at 1.25mg/kg orally.

IT 180421-65-2P 180421-66-3P 180421-67-4P
180421-68-5P 180421-69-6P 180421-70-9P
180421-71-0P 180421-72-1P 180421-73-2P
180421-74-3P 180421-75-4P 180421-76-5P
180421-77-6P 180421-78-7P 180421-79-8P
180421-80-1P 180421-81-2P 180421-82-3P
180421-83-4P 180421-85-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 6-[triazolyl(3-trifluoromethylphenyl)methyl]-2-quinolin(thi)ones for treatment of keratinization disorders)

RN 180421-65-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 180421-66-3 CAPLUS

CN 2(1H)-Quinolinone, 6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 180421-67-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 180421-68-5 CAPLUS
CN 2(1H)-Quinolinone, 6-[1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)



RN 180421-69-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[fluoro-1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 180421-70-9 CAPLUS

CN 2(1H)-Quinolinone, 6-[1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]propyl]- (CA INDEX NAME)



RN 180421-71-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-methyl-1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]propyl]- (CA INDEX NAME)



RN 180421-72-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]pentyl]- (CA INDEX NAME)



RN 180421-73-2 CAPLUS
CN 2(1H)-Quinolinone, 8-methyl-6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 180421-74-3 CAPLUS
CN 2(1H)-Quinolinone, 5-chloro-6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 180421-75-4 CAPLUS
CN 2(1H)-Quinolinone, 8-fluoro-6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 180421-76-5 CAPLUS
CN 2(1H)-Quinolinone, 1-fluoro-6-[1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)



RN 180421-77-6 CAPLUS
CN 2(1H)-Quinolinone, 1-methyl-6-[1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)



RN 180421-78-7 CAPLUS
CN 2(1H)-Quinolinone, 1-ethyl-6-[1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)



RN 180421-79-8 CAPLUS
CN 2(1H)-Quinolinone, 1-methyl-6-[1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]propyl]- (CA INDEX NAME)



RN 180421-80-1 CAPLUS
CN 2(1H)-Quinolinone, 1-methyl-6-[1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]butyl]- (CA INDEX NAME)



RN 180421-81-2 CAPLUS
CN 2(1H)-Quinolinone, 1-methyl-6-[1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]pentyl]- (CA INDEX NAME)



RN 180421-82-3 CAPLUS
CN 2(1H)-Quinolinone, 1-methyl-6-[3-methyl-1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]butyl]- (CA INDEX NAME)



RN 180421-83-4 CAPLUS
CN 2(1H)-Quinolinone, 1-amino-6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 180421-85-6 CAPLUS
CN 2(1H)-Quinolinone, 1-methyl-6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]-, monohydrobromide, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HBr

L4 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	1994:217224 CAPLUS
DOCUMENT NUMBER:	120:217224
ORIGINAL REFERENCE NO.:	120:38557a,38560a
TITLE:	Studies of 1-alkyl-2(1H)-pyridone derivatives. XXXV. The Friedel-Crafts reaction of 1-methyl-2(1H)-pyridone homologs with benzoic acid derivatives
AUTHOR(S):	Fujita, Reiko; Yasugahira, Hiroaki; Tomisawa, Hiroshi
CORPORATE SOURCE:	Tohoku Coll. Pharm., Sendai, 981, Japan

SOURCE: Annual Report of the Tohoku College of Pharmacy (1992), 39, 91-9
CODEN: TYKNAQ; ISSN: 0495-7342
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
OTHER SOURCE(S): CASREACT 120:217224

AB The Friedel-Crafts reaction of 1-methyl-2(1H)-quinolone with o-bromobenzoyl chloride (I) gave 6-(o-bromobenzoyl)-1-methyl-2(1H)-quinolone in good yield. The reaction of 1,4-dimethyl-2(1H)-quinolone, 4-benzoyl-1-methyl-2(1H)-quinolone, or 2,3-dimethyl-1(2H)-isoquinolone with BzCl or Bz2O gave regioselectively 6-benzoyl-1,4-dimethyl-2(1H)-quinolone, 4,6-dibenzoyl-1-methyl-2(1H)-quinolone, or 4-benzoyl-2,3-dimethyl-1(2H)-isoquinolone, resp. The reaction of 2,6,7-trimethyl-1(2H)-isoquinolone with I gave 5-(o-bromobenzoyl)-2,6,7-trimethyl-1(2H)-isoquinolone.

IT 153888-51-8P, 6-(o-Bromobenzoyl)-1-methyl-2(1H)-quinolone
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 153888-51-8 CAPLUS

CN 2(1H)-Quinolinone, 6-(2-bromobenzoyl)-1-methyl- (CA INDEX NAME)



L4 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1992:592207 CAPLUS
DOCUMENT NUMBER: 117:192207
ORIGINAL REFERENCE NO.: 117:33223a,33226a
TITLE: Fluorine-19 NMR studies on the mechanism of riboflavin synthase. Synthesis of 6-(trifluoromethyl)-7-oxo-8-(D-ribityl)lumazine and 6-(trifluoromethyl)-7-methyl-8-(D-ribityl)lumazine
AUTHOR(S): Cushman, Mark; Patel, Hemantkumar H.; Scheuring, Johannes; Bacher, Adelbert
CORPORATE SOURCE: Sch. Pharm. Pharm. Sci., Purdue Univ., West Lafayette, IN, 47907, USA
SOURCE: Journal of Organic Chemistry (1992), 57(21), 5630-43
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title oxo-(D-ribityl)lumazine I was synthesized by reaction of Me trifluoropyruvate with 5-amino-6-(D-ribitylamino)pyrimidine-2,4(1H,3H)-dione hydrochloride and utilized as a 19F NMR probe of the light riboflavin synthase of Bacillus subtillis. I was found to be an inhibitor of riboflavin synthase with an inhibition constant KI = 55 μM. The

enzyme-bound ligand gave rise to several broad 19F NMR signals which were shifted to low field. The bound ligand I could be displaced from the enzyme by the enzyme product, riboflavin (II), and the product analog, 5-nitroso-6-(ribitylamino)-2,4(1H,3H)-pyrimidinedione. Title methyl-(D-ribityl)lumazine III was synthesized by reaction of 5-amino-6-(D-ribitylamino)pyrimidine-2,4(1H,3H)-dione hydrochloride with 1,1,1-trifluorobutane-2,3-dione. Three mols. of III can be bound relatively tightly per mol of riboflavin synthase, i.e., one ligand mol. per protein subunit. A scheme for the catalytic cycle of riboflavin synthase is proposed.

IT 143309-79-9P 143309-80-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 143309-79-9 CAPLUS

CN 2(1H)-Quinoxalinone, 6-benzoyl-3-(trifluoromethyl)- (CA INDEX NAME)



RN 143309-80-2 CAPLUS

CN 2(1H)-Quinoxalinone, 7-benzoyl-3-(trifluoromethyl)- (CA INDEX NAME)



L4 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1992:571381 CAPLUS

DOCUMENT NUMBER: 117:171381

ORIGINAL REFERENCE NO.: 117:29633a,29636a

TITLE: Synthesis of pyrido[1',2':1,2]imidazo[4,5-b]quinoxalines

AUTHOR(S): Tanaka, Kiyoshi; Takahashi, Hideki; Takimoto, Kozo; Sugita, Masahiko; Mitsuhashi, Keiryo

CORPORATE SOURCE: Fac. Eng., Seikei Univ., Musahino, 180, Japan

SOURCE: Journal of Heterocyclic Chemistry (1992), 29(4), 771-7
CODEN: JHTCAD; ISSN: 0022-152X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 117:171381

GI



I



II



III



IV

AB Synthesis of title compds. I (R = H, 8-, 9-Cl, 8-, 9-Bz, 8-, 9-NO2; R1 = H, 1-, 2-, 3-, 4-Me, 4-PhCH2O) by the facile cyclizations of 2,3-dichloroquinoxalines II with 2-aminopyridines III and of 2-amino-3-chloroquinoxalines IV (R ≠ H) with various substituted pyridines is described.

IT 143702-68-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(chlorination of)

RN 143702-68-5 CAPLUS

CN 2,3-Quinoxalinedione, 6-benzoyl-1,4-dihydro- (CA INDEX NAME)



L4 ANSWER 19 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1990:612014 CAPLUS

DOCUMENT NUMBER: 113:212014

ORIGINAL REFERENCE NO.: 113:35835a,35838a

TITLE: Preparation of (1H-azol-1-ylmethyl)quinolines, -quinazolines, and -quinoxalines as drugs

INVENTOR(S): Freyne, Eddy Jean Edgard; Venet, Marc Gaston; Raeymaekers, Alfons Herman Margaretha; Sanz, Gerard Charles

PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.

SOURCE: Eur. Pat. Appl., 106 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 371564	A2	19900606	EP 1989-203014	19891128 <--
EP 371564	A3	19910529		
EP 371564	B1	19950712		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5028606	A	19910702	US 1989-434957	19891113 <--
US 5037829	A	19910806	US 1989-435120	19891113 <--
CA 2002864	A1	19900529	CA 1989-2002864	19891114 <--
CA 2002864	C	19991116		

DK	8905994	A	19900530	DK 1989-5994	19891128 <--
DK	172748	B1	19990628		
NO	8904734	A	19900530	NO 1989-4734	19891128 <--
NO	174509	B	19940207		
NO	174509	C	19940518		
AU	8945646	A	19900607	AU 1989-45646	19891128 <--
AU	620946	B2	19920227		
HU	52498	A2	19900728	HU 1989-6220	19891128 <--
HU	205106	B	19920330		
ZA	8909076	A	19910731	ZA 1989-9076	19891128 <--
SU	1780536	A3	19921207	SU 1989-4742543	19891128 <--
IL	92486	A	19930708	IL 1989-92486	19891128 <--
ES	2088889	T3	19961001	ES 1989-203014	19891128 <--
FI	101964	B	19980930	FI 1989-5687	19891128 <--
FI	101964	B1	19980930		
CN	1042912	A	19900613	CN 1989-108925	19891129 <--
CN	1033752	B	19970108		
JP	02223579	A	19900905	JP 1989-307793	19891129 <--
JP	2916181	B2	19990705		
US	5151421	A	19920929	US 1991-672298	19910320 <--
US	5185346	A	19930209	US 1991-704746	19910523 <--
US	5268380	A	19931207	US 1992-973871	19921110 <--
US	5441954	A	19950815	US 1993-131817	19931005 <--
CN	1106004	A	19950802	CN 1994-117801	19941102 <--
CN	1036002	B	19971001		
CN	1106005	A	19950802	CN 1994-117802	19941102 <--
CN	1036003	B	19971001		
US	5612354	A	19970318	US 1995-409551	19950323 <--

PRIORITY APPLN. INFO.:

GB 1988-27820	A	19881129
GB 1988-27821	A	19881129
GB 1988-27822	A	19881129
US 1989-434205	B2	19891113
US 1989-434957	A3	19891113
US 1991-704746	A3	19910523
US 1992-973871	A3	19921110
US 1993-131817	A3	19931005

OTHER SOURCE(S): MARPAT 113:212014

GI For diagram(s), see printed CA Issue.

AB The title compds. [I; R = H, alkyl; X1:X2 = CH:CH, CH:N, N:CH; Y = H, alkyl, cycloalkyl, alkenyl, alkynyl, (un)substituted aryl, aralkyl; Z = (un)substituted (oxo)quinolinyl, (oxo- or thioxo)quinazolinyl, (oxo- or dioxo)quinoxalinyl] were prepared as retinoic acid metabolism inhibitors, aromatase inhibitors, etc. Thus, 3,4-dihydroquinolin-2(1H)-one was stirred 2 h at 70° with BzCl in DMF containing AlCl3 and the product reduced by NaBH4 to give hydroxymethylquinolinone II (R1 = Ph, R2 = OH). II (R1 = Me, R2 = OH) was stirred overnight with SOCl2 in THF and the product II (R1 = Me, R2 = Cl) stirred overnight at 60-70° with 1H-imidazole in DMSO to give II (R1 = Me, R2 = imidazolo) which maintained plasma levels of i.v. administered all-trans-retinoic acid at ≥10 ng/mL in rats 2 h after oral administration of 40 mg/kg.

IT 120067-41-6P 130344-00-2P 130344-01-3P
130344-02-4P 130344-03-5P 130346-18-8P
130346-22-4P 130346-25-7P 130346-26-8P
130346-27-9P 130346-30-4P 130346-32-6P
130346-33-7P 130346-36-0P 130346-38-2P
130346-40-6P 130346-41-7P 130346-42-8P
130346-50-8P 130346-51-9P 130346-66-6P
130346-67-7P 130346-68-8P 130346-69-9P
130346-70-2P 130346-74-6P 130346-78-0P
130347-21-6P 130347-22-7P 130347-23-8P
130347-24-9P 130347-25-0P 130347-26-1P
130347-27-2P 130347-28-3P 130347-29-4P

130347-30-7P 130347-31-8P 130347-33-0P
130347-35-2P 130347-37-4P 130347-38-5P
130347-39-6P 130347-40-9P 130347-41-0P
130347-42-1P 130347-44-3P 130347-45-4P
130347-46-5P 130347-47-6P 130347-48-7P
130347-62-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as retinoate metabolism and aromatase inhibitor)

RN 120067-41-6 CAPLUS
CN 2(1H)-Quinolinone, 6-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)



RN 130344-00-2 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)



RN 130344-01-3 CAPLUS
CN 2(1H)-Quinolinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)



RN 130344-02-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[(3-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)



RN 130344-03-5 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)



RN 130346-18-8 CAPLUS
CN 2(1H)-Quinoxalinone, 6-(1H-imidazol-1-ylphenylmethyl)-3-methyl- (CA INDEX NAME)



RN 130346-22-4 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[1H-imidazol-1-yl[3-(trifluoromethyl)phenyl]methyl]-3-methyl- (CA INDEX NAME)



RN 130346-25-7 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(2-fluorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl- (CA INDEX NAME)



RN 130346-26-8 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-fluorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl-

(CA INDEX NAME)



RN 130346-27-9 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl-
(CA INDEX NAME)



RN 130346-30-4 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl-
(CA INDEX NAME)



RN 130346-32-6 CAPLUS
CN 2(1H)-Quinoxalinone, 1-butyl-6-(1H-imidazol-1-ylphenylmethyl)-3-methyl-
(CA INDEX NAME)



RN 130346-33-7 CAPLUS

CN 2(1H)-Quinoxalinone, 6-(1H-imidazol-1-ylphenylmethyl)-1,3-dimethyl- (CA INDEX NAME)



RN 130346-36-0 CAPLUS
CN 2(1H)-Quinoxalinone, 7-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl- (CA INDEX NAME)



RN 130346-38-2 CAPLUS
CN 2(1H)-Quinoxalinone, 7-[(3-fluorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl- (CA INDEX NAME)



RN 130346-40-6 CAPLUS
CN 2(1H)-Quinoxalinone, 7-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 130346-39-3
CMF C19 H15 F N4 O



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 130346-41-7 CAPLUS
CN 2(1H)-Quinoxalinone, 1-amino-6-(1H-imidazol-1-ylphenylmethyl)-3-methyl- (CA INDEX NAME)



RN 130346-42-8 CAPLUS
CN 2(1H)-Quinoxalinone, 6-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)



RN 130346-50-8 CAPLUS
CN 2(1H)-Quinoxalinone, 7-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)



RN 130346-51-9 CAPLUS

CN 2(1H)-Quinoxalinone, 6-(1H-imidazol-1-ylphenylmethyl)-3-phenyl- (CA INDEX NAME)



RN 130346-66-6 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl- (CA INDEX NAME)



RN 130346-67-7 CAPLUS
CN 2(1H)-Quinoxalinone, 7-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl- (CA INDEX NAME)



RN 130346-68-8 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(1H-imidazol-1-yl)(4-methoxyphenyl)methyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 130346-69-9 CAPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-6-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)



RN 130346-70-2 CAPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-7-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)



RN 130346-74-6 CAPLUS
CN 2(1H)-Quinoxalinone, 7-[1H-imidazol-1-yl(4-methylphenyl)methyl]-3-methyl- (CA INDEX NAME)



RN 130346-78-0 CAPLUS
CN 2(1H)-Quinoxalinone, 7-[1H-imidazol-1-yl(4-methoxyphenyl)methyl]-3-methyl- (CA INDEX NAME)



RN 130347-21-6 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-phenyl-, 4-oxide (CA INDEX NAME)



RN 130347-22-7 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-phenyl-
(CA INDEX NAME)



RN 130347-23-8 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[1H-imidazol-1-yl[4-(1-methylethyl)phenyl]methyl]-3-
methyl- (CA INDEX NAME)



RN 130347-24-9 CAPLUS
CN 2(1H)-Quinoxalinone, 7-[1H-imidazol-1-yl[4-(1-methylethyl)phenyl]methyl]-3-
methyl- (CA INDEX NAME)



RN 130347-25-0 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-, 4-oxide
(CA INDEX NAME)



RN 130347-26-1 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)



RN 130347-27-2 CAPLUS
CN 2(1H)-Quinoxalinone, 7-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-(2-methylpropyl)- (CA INDEX NAME)



RN 130347-28-3 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-(2-methylpropyl)- (CA INDEX NAME)



RN 130347-29-4 CAPLUS
CN 2(1H)-Quinoxalinone, 7-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-propyl-

(CA INDEX NAME)



RN 130347-30-7 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-propyl-
(CA INDEX NAME)



RN 130347-31-8 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-(1-
methylethyl)- (CA INDEX NAME)



RN 130347-33-0 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]- (CA
INDEX NAME)



RN 130347-35-2 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-phenyl-, 4-oxide (CA INDEX NAME)



RN 130347-37-4 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-propyl- (CA INDEX NAME)



RN 130347-38-5 CAPLUS
CN 2(1H)-Quinoxalinone, 7-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-propyl- (CA INDEX NAME)



RN 130347-39-6 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-(1-methylpropyl)- (CA INDEX NAME)



RN 130347-40-9 CAPLUS
CN 2(1H)-Quinoxalinone, 7-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-(1-methylpropyl)- (CA INDEX NAME)



RN 130347-41-0 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-(1-methylethyl)- (CA INDEX NAME)



RN 130347-42-1 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-phenyl- (CA INDEX NAME)



RN 130347-44-3 CAPLUS
CN 2(1H)-Quinoxalinone, 3-benzoyl-6-(1H-imidazol-1-ylphenylmethyl)-, 4-oxide (CA INDEX NAME)



RN 130347-45-4 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)



RN 130347-46-5 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(2-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)



RN 130347-47-6 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)



RN 130347-48-7 CAPLUS
CN 2(1H)-Quinoxalinone, 3-phenyl-6-(phenyl-1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)



RN 130347-62-5 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3,4-dichlorophenyl)-1H-imidazol-1-ylmethyl]-3-phenyl- (CA INDEX NAME)



L4 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1990:552215 CAPLUS
DOCUMENT NUMBER: 113:152215
ORIGINAL REFERENCE NO.: 113:25867a,25870a
TITLE: Studies on 1-alkyl-2(1H)-pyridone derivatives. XXXII. The Friedel-Crafts reaction of 1-alkyl-2(1H)-pyridone derivatives with acid anhydride
AUTHOR(S): Fujita, Reiko; Tomisawa, Hiroshi
CORPORATE SOURCE: Tohoku Coll. Pharm., Sendai, 981, Japan
SOURCE: Yakugaku Zasshi (1990), 110(6), 449-52
CODEN: YKKZAJ; ISSN: 0031-6903
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
OTHER SOURCE(S): CASREACT 113:152215
AB Reaction of N-benzyl- (I) and N-phenethyl-2(1H)-pyridone (II) with Bz2O (III) gave 5-benzoyl and 3,5-dibenzoyl compds. in good yields. Reactions of I and II with Ac2O gave only 5-acetyl compds. Reactions of dimethyl-2(1H)-pyridone bearing one Me group on the pyridone ring with III were carried out. Only 1,3-dimethyl-2(1H)-pyridone gave the 5-benzoyl-1,3-dimethyl compound; the others gave no benzoyl compound Reactions with Ac2O gave either a 5-acetyl compound or no acetyl compound Reactions of thiolactam compds. (thiopyridone, thioquinolone) with III gave 5-benzoylpyridone and 6-benzoylquinone in poor yields, resp.
IT 53995-93-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 53995-93-0 CAPLUS
CN 2(1H)-Quinolinone, 6-benzoyl-1-methyl- (CA INDEX NAME)



L4 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:407401 CAPLUS
DOCUMENT NUMBER: 111:7401

ORIGINAL REFERENCE NO.: 111:1422h,1423a
TITLE: Imidazole- or pyridine-containing carbostyrils as combined thromboxane synthetase and cyclic-AMP phosphodiesterase inhibitors, their preparation, and pharmaceuticals containing them
INVENTOR(S): Walker, Keith A. M.; Bruno, John J.; Martinez, Gregory R.
PATENT ASSIGNEE(S): Syntex (U.S.A.), Inc., USA
SOURCE: U.S., 20 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4792561	A	19881220	US 1986-868845	19860529 <--
US 4921862	A	19900501	US 1988-247134	19880921 <--

PRIORITY APPLN. INFO.: US 1986-868845 A3 19860529
OTHER SOURCE(S): CASREACT 111:7401; MARPAT 111:7401
GI



I

AB Title compds. I [X = R1CR2, cis- or trans-CR3:CR4; R1 = H when R2 = OH, or R1 = Ph, phenylalkyl when R2 = H, OH; Ph is optionally monosubstituted; or R1R2 = O, C1-6 alkylidene, (substituted) benzylidene; R3 = H, C1-6 alkyl; R4 = H; R3R4 = bond; n = 0-3; R = 1-imidazolyl; dotted line = optional covalent bond] are prepared as thromboxane synthetase and cAMP phosphodiesterase inhibitors for treatment of disease characterized by elevated thromboxane levels or an imbalance of prostacyclin/thromboxane levels (no data). A mixture of CuI 11.6, (Ph3P)2PdCl2 86, N-propargylimidazole (preparation given) 774 mg, and 6-bromo-3,4-dihydrocarbostyril 1.5 g was stirred in 10mL pyridine and 2 mL triethylamine at 100° for 48 h under N. The reaction mixture was then treated with saturated aqueous K2CO3, extracted with 10% MeOH in CH2Cl2, and worked up to give 6-[3-(imidazol-1-yl)-1-propyn-1-yl]-3,4-dihydrocarbostyril. The latter (502 mg) was stirred under H in the presence of 200 mg 10% Pd/C to give 6-[3-(imidazol-1-yl)propyl]-3,4-dihydrocarbostyril (II). A tablet was formulated containing II 25, cornstarch 20, spray-dried lactose 153, and Mg stearate 2 mg.

IT 120067-41-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as cAMP phosphodiesterase and thromboxane synthetase inhibitors)
RN 120067-41-6 CAPLUS
CN 2(1H)-Quinolinone, 6-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)



L4 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:610869 CAPLUS
DOCUMENT NUMBER: 109:210869
ORIGINAL REFERENCE NO.: 109:34879a,34882a
TITLE: Carbinolamine equivalents in the 8-aminotetrahydroisoquinoline series
AUTHOR(S): Moehrle, Hans; Biegholdt, Martin
CORPORATE SOURCE: Inst. Pharm. Chem., Univ. Duesseldorf, Duesseldorf, 4000/1, Fed. Rep. Ger.
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1988), 321(5), 287-91
CODEN: ARPMAS; ISSN: 0365-6233
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 109:210869
GI



AB Hg(II)-EDTA dehydrogenations of the tetrahydroisoquinolines I (R = H, Ph) do not yield the expected pure carbinolamines, but the dimers II in an intermol. reaction. The acetylation of the dimers or of the iminium salts III generates the tricyclic primary products IV which undergo cleavage when the reaction time is prolonged.

IT 117366-00-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 117366-00-4 CAPLUS

CN Acetamide, N-[2-(1,2-dihydro-2-oxo-5-quinolinyl)-2-phenylethyl]-N-methyl-

(CA INDEX NAME)



L4 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1979:153494 CAPLUS
DOCUMENT NUMBER: 90:153494
ORIGINAL REFERENCE NO.: 90:24415a,24418a
TITLE: Fluorescent dyes
INVENTOR(S): Eckstein, Udo; Theidel, Hans
PATENT ASSIGNEE(S): Bayer A.-G., Fed. Rep. Ger.
SOURCE: Ger. Offen., 41 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2730644	A1	19790125	DE 1977-2730644	19770707 <--
EP 346	A1	19790124	EP 1978-100253	19780628 <--
EP 346	B1	19800109		
R: CH, DE, FR, GB				
JP 54017933	A	19790209	JP 1978-81040	19780705 <--
US 4184977	A	19800122	US 1978-922186	19780705 <--

PRIORITY APPLN. INFO.: DE 1977-2730644 19770707
GI



AB Fluorescent quinoxalines of general structure I were prepared, where R and R1 = H, halogen, alkyl, alkenyl, OH, alkoxy, aryloxy, amino, or substituted amino, R2 = H or an aryl or heterocyclic group, and n = 0, 1, or 2. I are especially useful as fluorescent whiteners. Thus, condensation of 2-(4-formylphenyl)benzoxazole [27395-93-3] with 2,3-dimethoxy-6-(dimethoxyphosphonomethyl)quinoxaline [69722-49-2] in DMF to which NaOMe was added portionwise gave I [R = R1 = MeO, n = 1, R2 = 2-benzoxazolyl (para position)] [69722-71-0], which showed a reddish blue fluorescence when dissolved in DMF and a fast, strong whitening effect in poly(ethylene terephthalate). Other I were similarly prepared
IT 69722-55-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(preparation and reaction with thionyl chloride)
RN 69722-55-0 CAPLUS
CN 2,3-Quinoxalinedione, 6-[2-[4-(2-benzoxazolyl)phenyl]ethenyl]-1,4-dihydro-
(CA INDEX NAME)



L4 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:443155 CAPLUS
DOCUMENT NUMBER: 83:43155
ORIGINAL REFERENCE NO.: 83:6819a,6822a
TITLE: 1-Alkyl-2(1H)-pyridone derivatives. XXIV. Friedel-Crafts reaction of 1-methyl-2(1H)-pyridone and its derivatives with acid anhydride
AUTHOR(S): Tomisawa, Hiroshi; Fujita, Reiko; Hongo, Hiroshi; Kato, Hideki
CORPORATE SOURCE: Tohoku Coll. Pharm., Sendai, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1975), 23(3), 592-6
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The Friedel-Crafts reactions of 1-methyl-2(1H)-pyridone (I), 2-methyl-1(2H)-isoquinolone (II), and 1-methyl-2(1H)-quinolone (III) with acid anhydrides, principally Bz2O, were carried out. In the case of I and II, reaction with acid anhydride gave the products in a good yield, but in the case of III, the reaction with acid anhydride gave products in much less yield than that with acid chloride.
IT 53995-93-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 53995-93-0 CAPLUS
CN 2(1H)-Quinolinone, 6-benzoyl-1-methyl- (CA INDEX NAME)



L4 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1974:551956 CAPLUS
DOCUMENT NUMBER: 81:151956
ORIGINAL REFERENCE NO.: 81:23681a,23684a
TITLE: 1-Alkyl-2(1H)-pyridone derivatives. XXII. Friedel-Crafts reaction of 1-methyl-2(1H)-pyridone and its homologs with benzoyl chloride

AUTHOR(S): Tomisawa, Hiroshi; Fujita, Reiko; Hongo, Hiroshi; Kato, Hideki
CORPORATE SOURCE: Tohoku Coll. Pharm., Sendai, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1974), 22(9), 2091-6
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Friedel-Crafts reaction of 1-methyl-2(1H)-pyridone, 1-methyl-2(1H)-quinolone, and 2-methyl-1 (2H)-isoquinolone with BzCl gave 5-benzoyl-1-methyl-2(1H)-pyridone, 3-benzoyl-1-methyl-2(1H)-pyridone, and 3,5-dibenzoyl-1-methyl-2(1H)-pyridone; 3-benzoyl-1-methyl-2-(1H)-quinolone and 6-benzoyl-1-methyl-2(1H)-quinolone; and 4-benzoyl-2-methyl-1-(2H)-isoquinolone and 5-benzoyl-2-methyl-1(2H)-isoquinolone, resp.

IT 53995-93-0P
RL: PREP (Preparation)
(by Friedel-Craft acylation)

RN 53995-93-0 CAPLUS

CN 2(1H)-Quinolinone, 6-benzoyl-1-methyl- (CA INDEX NAME)



L4 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1963:462385 CAPLUS
DOCUMENT NUMBER: 59:62385
ORIGINAL REFERENCE NO.: 59:11514c-h,11515a
TITLE: Dihydroquinoxal-2-ones
INVENTOR(S): Zellner, Hugo; Pailer, Matthias; Pruckmayr, Gerfried
PATENT ASSIGNEE(S): Donau-Pharmazie G.m.b.H.
SOURCE: 12 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
AT 228204		19630710	AT	19590703 <--

PRIORITY APPLN. INFO.: AT 19590703

GI For diagram(s), see printed CA Issue.

AB New dihydroquinoxal-2-ones (I), in which R1, R2, R3, R7, and R8 are H, halogen, alkyl, OH, alkoxy, acyloxy, alkyloxy, NH2, monoalkylamino, dialkylamino, acylamino, NO2, or alkylthio groups, R4 is dialkylaminoalkyl, aminoalkyl, N-alkylpiperidyl or N-alkylmorpholyl, and R5 and R6 are H, alkyl with up to 5 C atoms, OH, acyloxy, alkyloxy, NH2, acylamino, monoalkylamino, or dialkyl amino groups, and the salts thereof are prepared by treating the resp. o-phenylene diamines with suitably substituted phenylpyruvic acids or derivs. thereof to obtain the dihydroquinoxalones, which are then aminoalkylated at the 1-N atom with an amino alc. and subsequently aminated. The compds. obtained may be converted into salts. Thus, there have been prepared: 1-(diethylaminoethyl)-3-benzyldihydroquinoxal-2-one, m. 31°; 1-(diethylaminoethyl)-3-(4-

methoxybenzyl)dihydroquinoxal-2-one; 1-(diethylaminoethyl)-3-(3,4-dimethoxybenzyl)dihydroquinoxal-2-one, m. 192°; 1-(diethylaminoethyl)-3-(3,4-methylenedioxybenzyl)dihydroquinoxal-2-one, light yellow oil; 1-(diethylaminoethyl)-3-(3,4-dimethoxybenzyl)-6-chlorodihydroquinoxal-2-one, b0.5 240-6°; 6-chloro-3-(4-methoxybenzyl)-1-diethylaminoethyldihydroquinoxal-2-one, b0.01 210°; 3-(4-nitrobenzyl)-1-diethylaminoethyldihydroquinoxal-2-one, b0.03-0.05 170-5°; 3-(4-dimethylaminobenzyl)-1-diethylaminoethyldihydroquinoxal-2-one, b0.01 200-10°; 6(7)-methoxy-3-(3,4-dimethoxybenzyl)-1-diethylaminoethyldihydroquinoxal-2-one, b0.01 220°; 6(7)-methyl-3-(4-methoxybenzyl)-1-diethylaminoethyldihydroquinoxal-2-one, b0.01 200°; 3-(4-chlorobenzyl)-1-diethylaminoethyldihydroquinoxal-2-one, b0.01 185-90°; 3-(4-methoxybenzyl)dihydroquinoxal-2-one, m. 198°; 3-(3,4-methylenedioxybenzyl)dihydroquinoxal-2-one, m. 220°; 6(7)-methoxy-3-benzyldihydroquinoxal-2-one, 2 isomers, m. 185 and 199°, resp.; 6(7)-methoxy-3-(4-methoxybenzyl)dihydroquinoxal-2-one, m. 190°; 6(7)-chloro-3-(4-methoxybenzyl)dihydroquinoxal-2-one, m. 227-9°; 6(7)-nitro-3-(4-methoxybenzyl)dihydroquinoxal-2-one, m. 192-7°; 6(7)-methoxy-3-(3,4-dimethoxybenzyl)dihydroquinoxal-2-one, m. 171°, 6(7)-methoxy-3-(3,4-methylenedioxybenzyl)dihydroquinoxal-2-one, m. 215°; 6,7-dimethoxy-3-benzyldihydroquinoxal-2-one, m. 275°; 3-(4-ethoxybenzyl)dihydroquinoxal-2-one, m. 196°; 3-(p-chlorobenzyl)dihydroquinoxal-2-one, m. 180° (decomposition); 3-(p-hydroxybenzyl)dihydroquinoxal-2-one, m. 246°; 3-(4-methoxyphenyl)-α-ethyldihydroquinoxal-2-one, m. 205°; 6(7)-methoxy-3-(3,4-dimethoxybenzyl)-1-diethylaminoethyldihydroquinoxal-2-one, b0.01 220°; 3-(4-ethoxybenzyl)-1-diethylaminoethyldihydroquinoxal-2-one, m. 62°; 6(7)-methoxy-3-benzyl-1-diethylaminoethyldihydroquinoxal-2-one, b0.01 204-8°; 3-(4-methoxybenzyl)-1-morpholinoethyldihydroquinoxal-2-one, m. 151°; 6(7)-chloro-3-(4-methoxybenzyl)-1-morpholinoethyldihydroquinoxal-2-one, b0.005 200°; 6(7)-methoxy-3-(3,4-methylendioxybenzyl)-1-morpholinoethyldihydroquinoxal-2-one, m. 201°, b0.01 200-10°; 3-benzyl-1-morpholinoethyldihydroquinoxal-2-one, b0.005 203°; 6(7)-chloro-3-(4-methoxybenzyl)-1-diethylaminoethyldihydroquinoxal-2-one, b0.01 210°, m. 78-9°; 6,7-dimethoxy-3-benzyl-1-diethylaminoethyldihydroquinoxal-2-one, b0.005 230°; 1-piperidinomethyl-3-benzyldihydroquinoxal-2-one, m. 211-12°. The compds. are useful as analgesics; they have papaverine- and morphine-like activity.

IT 92868-65-0
(Derived from data in the 7th Collective Formula Index (1962-1966))

RN 92868-65-0 CAPLUS

CN 2(1H)-Quinoxalinone, 5-piperonyl- (7CI) (CA INDEX NAME)



L4 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1963:403525 CAPLUS
DOCUMENT NUMBER: 59:3525
ORIGINAL REFERENCE NO.: 59:626h,627a-d
TITLE: Synthesis of quinoxalone derivatives
AUTHOR(S): Pailer, M.; Pruckmayr, G.; Zellner, H.; Zellner, Gertraud
CORPORATE SOURCE: Univ. Vienna
SOURCE: Monatshefte fuer Chemie (1962), 93, 1005-18
CODEN: MOCMB7; ISSN: 0026-9247
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 59:3525

GI For diagram(s), see printed CA Issue.

AB The synthesis of a series of substituted 3-benzylquinoxal-2-ones is described. These could be expected to possess a similar pharmacol. activity to the analogous benzimidazole derivs. of similar structure. I were prepared either by condensing the corresponding phenylpyruvic acid with N-diethylaminoethyl- or N-morpholinoethyl-o-phenylenediamine, or by first preparing the quinoxolone then alkylating with diethylaminoethyl chloride [or morpholinoethyl (MA) chloride] and sodamide in absolute dioxane or with K2CO3 in absolute xylene. Similarly prepared were II (R, R1, m.p. given): H, H, 312°; OMe, H, 267.5-8.5°; H, Et2NCH2CH2, 99.5-101°. R, R1, R2, R3, R4, m.p.; H, H, H, H, H, 196°; OMe, H, H, H, H, 198°; OEt, H, H, H, H, 196°; OCH2O, , H, H, H, 220°; H, H, OMe(H), H(OMe), H, 185°; H, H, H(OMe), OMe(H), H, 200°; H, H, OMe, OMe, H, 275°; OH, H, H, H, H, 243-6°; , , , , , (decomposition); OMe, OMe, Cl(H), H(Cl), H, 201-2°; OMe, H, Cl(H), H(Cl), H, 220-2°; OMe, H, H(Cl), Cl(H), H, 227-9°; NO2, H, H, H, H, 268-9°; Cl, H, H, H, H, 231°; OMe, H, NO2(H), H, (NO2), H, 192-7°; OMe, H, Me(H), H(Me), H, 202-3°; OMe, H, CO2Me(H), H(CO2Me), H, 167-8°; OMe, H, benzo, , 264°; H, H, H, H, H, Et2NCH2CH2, -; OMe, H, H, H, Et2NCH2CH2, 69° (HCl salt m. 188°); OMe, OMe, H, H, Et2NCH2CH2, - (HCl salt m. 192°); OCH2O, , H, H, Et2NCH2CH2, - (HCl salt m. 220°); OEt, H, H, H, Et2NCH2CH2 61°; OMe, OMe, Cl(H), H(Cl), Et2NCH2CH2, -; OMe, H, H, (Cl), Cl(H), Et2NCH2CH2, 78-9°; Cl, H, H, H, Et2NCH2CH2, 73-5°; OMe, H, Me(H), H(Me), Et2NCH2CH2, 69-70°; H, H, H, H, MA, -; OMe, H, H, H, MA, 151°; Also prepared was III; HCl salt m. 207-10°.

IT 92868-65-0
(Derived from data in the 7th Collective Formula Index (1962-1966))

RN 92868-65-0 CAPLUS

CN 2(1H)-Quinoxalinone, 5-piperonyl- (7CI) (CA INDEX NAME)



L4 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1940:12844 CAPLUS
DOCUMENT NUMBER: 34:12844

ORIGINAL REFERENCE NO.: 34:1986a-i,1987a
TITLE: Nitrogen heterocycles. XLVI. 4,6-Diaminoisophthalaldehyde. 3
AUTHOR(S): Ruggli, Paul; Frey, Hugo
SOURCE: Helvetica Chimica Acta (1939), 22, 1413-27
CODEN: HCACAV; ISSN: 0018-019X
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB The 3,6-dicarboxylic ester produced by the addition of 2 mols. AcCH2CO2Et to 4,6-diaminoisophthalaldehyde (I) was saponified to the free acid which was decarboxylated by heating with Cu in quinoline at 160-230° for 20 min. The resulting 2,7-dimethylbenzodipyridine (II) was converted into the hexa-Br derivative which was transformed by heating with oleum to the crude benzodipyridine-2,7-dicarboxylic acid (III). A mixture of 0.25 g. III, 2 cc. of 10% NH4OH and 2 cc. alc. was triturated, diluted with 20 cc. H2O and heated. The NH3-free product was diluted with 10 cc. H2O and boiled with 0.5 g. AgNO3 in 10 cc. H2O. The crude Ag salt (0.45 g.) was boiled with 70 cc. MeOH and 0.4 g. MeI for 1 h., filtered and concentrated to 20 cc., yielding 0.2 g. (70%) of yellow needles of di-Me benzodipyridine-2,7-dicarboxylate, C16H12N2O4, m. 272° (with darkening). Decarboxylation of III gave benzodipyridine (IV); perchlorate, m. 268° (explosive on rapid heating); MeI derivative, m. above 200° (decomposition). Reduction of 0.2 g. IV in 5 cc. of boiling AmOH with 0.35 g. Na and recrystn. from alc. gave octahydrobenzodipyridine, m. 111.5°, identified through the di-NO and di-Ac derivs., m. 179° (decomposition) and 143°, resp. Reduction of II with Na in AmOH gave as main product a resin which was converted into a colorless crystalline octahydro-2,7-dimethylbenzodipyridine diperchlorate, C14H22Cl2N2O8, m. 285-6° (decomposition). The resinous free base yielded 2 isomeric di-NO derivs., m. 164.5 and 151.5-2.0°, resp. Condensation of 0.2 g. II with 0.5 g. of p-Me2NC6H4CHO at 170-5° in the presence of 10 drops of piperidine produced 0.45 g. of orange-red 2,7-bis(p-dimethylaminostyryl)benzodipyridine, C32H30N4, m. about 340° (with darkening), dissolving in HCl to give violet, blue, green and yellow solns. with increasing acid concns. Condensation of II with o-C6H4(CO2Et)2 by heating in the presence of Na for 14 h. at 100° gave a scarlet crystalline powder which on sulfonation dyed wool and silk bluish red in an acid bath. A unilateral condensation of 0.6 g. I with 6 cc. AcCH2CO2Et occurred on heating in the presence of 9 drops of piperidine for 30 min. at 170°. The impure 3-acetyl-6-formyl-7-aminocarbostyril yielded yellow crystals of a pure Ac derivative, C14H12N2O4, m. 320-40° (decomposition). Treatment of 1 g. I in 100 cc. alc. at 30° with 14 g. of dry OHCCHNaCO2Et, boiling for 1 h. after standing for 3 days, filtering off the brown amorphous precipitate (V), adding 1 cc. H2O and standing for 8 days gave a Na salt which was dissolved in 50 cc. H2O, acidified with 10% HCl and recrystd. from dioxane, yielding di-Et 2,6-diaminoisophthalaldiformylacetate, C18H20N2O6, m. 250° (decomposition). V was dissolved in H2O, filtered and precipitated with dilute HCl.

The amorphous product (0.06 g.) was decarboxylated by heating in vacuo with 0.3 g. BaO and 0.5 g. Cu at 150° to yield a bright yellow sublimate of IV. Condensation of I with excess cyclohexanone in the presence of piperidine produced 2,3,6,7-bis (tetramethylene)-benzodipyridine, C20H20N2, m. 250-1° (with darkening); dipicrate, m. 195° (decomposition). A mixture of 8 g. I in 150 cc. alc., 24 cc. PhCH2CN and 12.5 cc. of 30% NaOH was heated for 30 min. on the steam bath. Working up and purification through the di-HCl salt gave a free base (VI), C24H18N4, m. 301°; tetra-Ac derivative, C32H26N4O4, m. 238.5-9.5° (decomposition). Saponification of VI with HCl produced a carboxyl derivative, C24H18N2O3, which gave a Na salt and a mono-Ac derivative, m. 365°. Condensation of 4 g. of 4,6-dinitroisophthalaldehyde with

8.4 g. of dry PhCH(Na)CO2H by heating with 34 cc. Ac2O and 1.2 g. ZnCl2 for 40 h. at 80° gave a powdery dicarboxylic acid which was esterified through the Ag salt to di-Me 4,6-dinitroisophthalalbis(phenylacetate), C26H20N2O8, m. 152.5-3.5°. Condensation of methazonic acid (VII) with o-H2NC6H4CHO yields 3-nitroquinoline and similarly a cold mixture of VII and I in the presence of a min. of HCl gave 20% of yellow-orange needles of a compound C16H14N6O5, m. 290° (decomposition), of undetd. composition

IT 855762-40-2P, 6-Quinolineacrylic acid, 7-amino-1,2-dihydro-2-oxo-α,3-diphenyl- 855762-42-4P, 6-Quinolineacrylic acid, 7-acetamido-1,2-dihydro-2-oxo-α,3-diphenyl-
RL: PREP (Preparation)
(preparation of)

RN 855762-40-2 CAPLUS

CN Benzeneacetic acid, α-[(7-amino-1,2-dihydro-2-oxo-3-phenyl-6-quinolinyl)methylene]- (CA INDEX NAME)



RN 855762-42-4 CAPLUS

CN Benzeneacetic acid, α-[[7-(acetylamino)-1,2-dihydro-2-oxo-3-phenyl-6-quinolinyl]methylene]- (CA INDEX NAME)



=> fil stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.68	335.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-22.40	-22.40

FILE 'STNGUIDE' ENTERED AT 18:48:27 ON 26 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 20, 2008 (20080620/UP).

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.12	335.75

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-22.40

STN INTERNATIONAL LOGOFF AT 18:49:34 ON 26 JUN 2008